TrangAston :verified: · @CastlTrAstonDrs
1348 followers · 2772 posts · Server med-mastodon.com

@asmicrobiology II for evaluating the activity, safety, efficacy, & of in ambulatory patients with mild/moderate . Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. vs placebo

#IDMastodon #viralimmunology #DrugDevelopment #phase #clinicaltrial #Antiviral #pharmacokinetics #bemnifosbuvir #COVID19

Last updated 1 year ago